PIK3CB
MOLECULAR TARGETphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) is targeted by 39 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PIK3CB
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ly 294002 | 4.84 | 126 |
| 2 | dactolisib | 4.25 | 69 |
| 3 | pi 103 | 4.17 | 64 |
| 4 | idelalisib | 4.13 | 61 |
| 5 | zstk 474 | 3.56 | 34 |
| 6 | cgs 15943 | 3.47 | 31 |
| 7 | buparlisib | 3.40 | 29 |
| 8 | ly294002 | 3.26 | 25 |
| 9 | pictilisib | 3.14 | 22 |
| 10 | omipalisib | 3.14 | 22 |
| 11 | lestaurtinib | 3.04 | 20 |
| 12 | quisinostat | 2.94 | 18 |
| 13 | ku 55933 | 2.94 | 18 |
| 14 | duvelisib | 2.94 | 18 |
| 15 | fimepinostat | 2.89 | 17 |
| 16 | apitolisib | 2.71 | 14 |
| 17 | alpelisib | 2.64 | 13 |
| 18 | pf 04691502 | 2.64 | 13 |
| 19 | sapanisertib | 2.64 | 13 |
| 20 | gedatolisib | 2.56 | 12 |
| 21 | vistusertib | 2.48 | 11 |
| 22 | gsk 461364 | 2.40 | 10 |
| 23 | copanlisib | 2.40 | 10 |
| 24 | azd 6482 | 2.30 | 9 |
| 25 | bimiralisib | 2.30 | 9 |
| 26 | azd 7648 | 2.30 | 9 |
| 27 | vs 5584 | 2.30 | 9 |
| 28 | bgt 226 free base | 2.20 | 8 |
| 29 | tg100 115 | 2.08 | 7 |
| 30 | elimusertib | 2.08 | 7 |
| 31 | voxtalisib | 2.08 | 7 |
| 32 | gsk 2636771 | 2.08 | 7 |
| 33 | gsk 1059615 | 1.95 | 6 |
| 34 | pilaralisib | 1.95 | 6 |
| 35 | azd 8186 | 1.79 | 5 |
| 36 | eganelisib | 1.79 | 5 |
| 37 | Wortmannin | 1.61 | 4 |
| 38 | Sirolimus | 0.69 | 1 |
| 39 | Resveratrol | 0.69 | 1 |
About PIK3CB as a Drug Target
PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 39 compounds with documented PIK3CB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PIK3CB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.